Stockreport

KalVista Pharmaceuticals Provides Update on Strong EKTERLY® Launch with Preliminary Fourth Quarter and Full Year 2025 Revenue Results [Yahoo! Finance]

KalVista Pharmaceuticals, Inc.  (KALV) 
Last kalvista pharmaceuticals, inc. earnings: 3/10 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: ir.kalvista.com
PDF 1,318 patient start forms received in the US through December, reflecting continued rapid adoption as first and only oral on-demand treatment for hereditary angioedema [Read more]